Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Vicki L. Sato sold 22,000 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total transaction of $112,200.00. Following the transaction, the director owned 1,298,391 shares in the company, valued at $6,621,794.10. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock opened at $5.49 on Friday. The stock’s fifty day moving average is $5.22 and its 200 day moving average is $7.09. Vir Biotechnology, Inc. has a one year low of $4.32 and a one year high of $14.45. The stock has a market cap of $758.94 million, a P/E ratio of -1.30 and a beta of 1.22.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). The business had revenue of $3.03 million for the quarter, compared to the consensus estimate of $8.59 million. Vir Biotechnology had a negative net margin of 2,769.04% and a negative return on equity of 47.46%. Vir Biotechnology’s revenue was down 94.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.48) earnings per share. Analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of Vir Biotechnology in a report on Thursday, May 22nd. The Goldman Sachs Group decreased their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.86.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vir Biotechnology in the 4th quarter worth $42,000. GAMMA Investing LLC increased its holdings in shares of Vir Biotechnology by 524.3% in the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock worth $46,000 after purchasing an additional 5,972 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology during the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. grew its holdings in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after buying an additional 1,999 shares in the last quarter. Finally, FORA Capital LLC bought a new stake in Vir Biotechnology in the 1st quarter worth approximately $70,000. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).